Research Discoveries Highlights
The Medical Research Institute is distinguished by its many important contributions to biomedical and behavioral research:
1950s: Development of the membrane oxygenator type heart-lung machine for use in open-heart surgery.
1960: Insights into the intellectual and behavioral after effects of viral encephalitis.
1965: Developed and implemented the first computer-based respiratory monitoring system in an intensive care unit in
1979: Designated as one of nine Public Health Service Alcohol Research Centers in the nation and the only center studying the epidemiology of alcohol problems.
1980: Found evidence for an abnormal antibody to the nerve cells in the blood serum of some amyotrophic lateral sclerosis (Lou Gehrig's disease) patients.
1981: Development of a computerized technique to measure visual abilities in infants as young as three weeks of age.
1981: Work demonstrating for the first time how cancer drugs are taken up by leukemia cells in tissue culture and how this correlates closely with uptake in patients.
1982: Method developed for isolating the enzyme inhibitor alpha-1-antitrypsin in sufficient quantities to use in replace ment therapy to prevent or control lung disease.
1982: Pioneered a pharmacological treatment for the correction of strabismus (crossed eyes).
1983: Developed leukapheresis for the treatment of hairy cell leukemia.
1984: First reported successful use of the Left Ventricle Assist Device as a "bridge" from critical cardiac failure to organ transplantation.
1984: Landmark national epidemiological study identified, for the first time, differences in the characteristics of groups at high risk for alcohol problems among whites, blacks, and hispanics.
1991: Method of diagnosing diabetes developed utilizing the intravital microscope to study the blood vessels under the nail fold.
1991: Seven year clinical trial established that treatment of isolated systolic hypertension helps to prevent strokes.
1992: First report in world's literature demonstrating the efficacy of the antibiotic Azithromydn in treatment of Mycobacterium avium complex in AIDS patients.
1992: Published the first report documenting that mutations in the tumor suppressor gene, p53, result in an aggressive form of breast cancer.
1994: Researchers obtain first glimpses of the role that the gene Id-1 may play in the development of breast cancer.
1997: CPMCRI launches its research program in complementary medicine.
2000: The Longevity Consortium at CPMCRI’s Coordinating Center is founded (supported by a grant from the National Institute on Aging) with the aim to test the function of gene variations that contribute to human longevity and aging.
2003: CPMCRI launches the Centers of Research in Clinical Excellence (CRCLE), which benefits patients by coupling state-of-the-art clinical care with advanced information gathering.
2007: The Addiction and Pharmacology Research Laboratory (APRL) opens on the St. Luke’s Campus of CPMC.
2012: Researchers at CPMCRI identified the first-ever blood test to determine rejection in kidney transplant patients, without the need for biopsy.
2014:The leadership of Stanley Leong, M.D. and Mohammed Kashani-Sabet, M.D. in melanoma research and their findings on predictors of sentinel lymph node metastasis in thin melanoma —in collaboration with the Sentinel Lymph Node Working Group—were highlighted by the American Society of Clinical Oncology (ASCO), published in the high-impact Journal of Clinical Oncology, and summarized in a daily news summary for all ASCO members as the lead story.
2015:A new approach to treating advanced ovarian cancer may significantly improve patients’ survival compared to standard chemotherapy regimens, according to results published by CPMCRI clinical investigator and gynecologic oncologist John Chan, M.D., in the March issue of the Journal of Clinical Oncology. In the study, Dr. Chan and colleagues provide 10-year data demonstrating long-term advantages of intraperitoneal (IP) therapy over standard intravenous therapy, and suggesting new approaches to personalized treatments.
Donald Hill, M.D.; Frank Gerbode, M.D.; John J. Osborn; Mogens Bramson